Elicio Therapeutics (ELTX) vs Mereo BioPharma Group (MREO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Elicio Therapeutics (ELTX) has outperformed Mereo BioPharma Group (MREO) over the past year, losing 82.8% versus a loss of 85.6%. Over five years, MREO leads with a -86.3% price change compared with -96.1% for ELTX. Mereo BioPharma Group is the larger company by market cap ($41.5 million vs $41.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELTX | MREO |
|---|---|---|
| Share price | $1.45 | $0.26 |
| Market cap | $41.05M | $41.52M |
| 1-day change | -3.33% | -5.45% |
| YTD return | -81.78% | -37.65% |
| 1-year return | -82.84% | -85.56% |
| 5-year return | -96.13% | -86.32% |
| EPS (TTM) | $-1.81 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $500.00K |
| Net income (latest FY) | $-39.57M | $-41.88M |
| Operating margin | — | -8021.40% |
| Net margin | — | -8375.60% |
| 52-week high | $16.00 | $2.37 |
| 52-week low | $1.25 | $0.20 |
| Distance from 52-week high | -90.94% | -89.03% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +842.76% | +653.85% |
| Average volume | 324.71K | 1.24M |
| Shares outstanding | 28.31M | 159.70M |
| Employees | 33 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Mereo BioPharma Group
MREO stock →Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
ELTX vs MREO FAQ
Which is bigger, Elicio Therapeutics or Mereo BioPharma Group?
Mereo BioPharma Group (MREO) is larger, with a market capitalization of $41.52M compared with $41.05M for Elicio Therapeutics (ELTX).
Which stock has performed better over the past year, ELTX or MREO?
ELTX returned -82.84% over the past 12 months, compared with -85.56% for MREO (price return, excluding dividends). Past performance does not predict future results.
Are Elicio Therapeutics and Mereo BioPharma Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.